

COVID-19 case definitions, diagnostic testing criteria, and surveillance across the pandemic's 25 highest burden countries

Amitabh B. Suthar^{1*}, Sara Schubert^{1*}, Julie Garon¹, Alexia Couture¹,
Amy M. Brown², Sana Charania¹

¹ International Task Force, Novel Coronavirus (COVID-19) Response, Centers for Disease Control and Prevention, Atlanta, GA, U.S.A

² Data, Analytics, and Visualization Task Force, Novel Coronavirus (COVID-19) Response, Centers for Disease Control and Prevention, Atlanta, GA, U.S.A

* These authors contributed equally to this work

Corresponding author: Dr. Amitabh Bipin Suthar, icf4@cdc.gov

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Running title: Global COVID-19 surveillance

Word Count: 3,144

References: 73

Funding: None

Abstract (250 words)

Objective: We compared suspect, probable, and confirmed case definitions, as well as diagnostic testing criteria, used in the COVID-19 pandemic's 25 highest burden countries to aid interpretation of global and national surveillance data.

Methods: We identified the COVID-19 pandemic's 25 countries with the highest disease burden based on the number of cumulative reported cases to the World Health Organization (WHO) as of 1 October 2020. We searched official websites of these countries for suspect, probable, and confirmed case definitions. Given that confirmation of COVID-19 usually requires diagnostic testing, we also searched for diagnostic testing eligibility criteria in these countries. Extracted case definitions and testing criteria were managed in a database and analyzed in Microsoft Excel.

Findings: We identified suspect, probable, and confirmed case definitions in 96%, 64%, and 100% of countries, respectively. Testing criteria were identified in 100% of countries. 56% of identified countries followed WHO recommendations for using a combination of clinical and epidemiological criteria as part of the suspect case definition. 75% of identified countries followed WHO recommendations on using clinical, epidemiological, and diagnostic criteria for probable cases. 72% of countries followed WHO recommendations on using PCR testing for confirming a case of COVID-19. Finally, 64% of countries used testing eligibility criteria at least as permissive as WHO.

Conclusion: There is marked heterogeneity in who is eligible for testing in countries and how countries define a case of COVID-19. This affects the ability to compare burden, transmission, and response impact estimates derived from case surveillance data across countries.

Background

Novel infectious pathogens can pose major challenges to global health and security. Tracking the geography, demographics, and suspected mode of transmission of these pathogens using a standardized case definition remains the foundation for surveillance. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first characterized in December 2019.¹ By January 2020, the first national case definition was developed² and the World Health Organization (WHO) declared novel coronavirus disease 2019 a public health emergency of international concern.³ WHO's interim guidance for global COVID-19 surveillance, released on 31 January 2020, included a hierarchy of confirmed, probable and suspect case definitions.⁴ This guidance encouraged the use of all available clinical, epidemiological and laboratory evidence for case classification purposes. In addition, it noted that countries may need to adapt the case definitions to their unique epidemiological situation. Recommendations for testing suspected cases and widespread testing were included based on transmission intensity, number of cases, and available resources.

Both WHO and national case definitions have evolved over time with growing knowledge about COVID-19 etiology and the myriad of ways the disease manifests after infection.⁴⁻⁶ Early on, surveillance emphasized a travel history to Wuhan, China, where the initial outbreak occurred, and a narrowly defined set of symptoms. However, the virus rapidly spread to other provinces in China and then internationally, and reports of patients who either experienced new symptoms or remained asymptomatic increased.⁷ Confirming a COVID-19 case relies on diagnostic testing and, therefore, testing capacity has played an important role in countries' COVID-19 surveillance efforts. The types of tests available have expanded to include molecular and antigen tests to detect the presence of the SARS-CoV-2 virus and serology tests to detect antibodies produced from previous SARS-CoV-2 infection.^{8,9} However, the availability of these tests and the resources needed to collect, handle, and process clinical specimens have varied widely across nations.¹⁰ Shortages of test kits and reagents and lack of laboratory capacity have forced many locales to make tough decisions about policies for testing.¹¹

Differences in case definitions pose a challenge not only to detect the true number of cases within countries, but also to understand the global burden of disease and adequately respond to

pandemics. While global guidelines have been developed for testing eligibility criteria and case definitions, these are usually reviewed at a national level and are subject to adaptation based on laboratory and health system considerations. Earlier evaluations of global COVID-19 case definitions do not reflect the latest changes to national case definitions and test eligibility criteria and do not target the full range of countries with the highest burden of disease.^{12–14} In this study, we analyze (1) national COVID-19 case definitions from the 25 countries with the largest number of reported COVID-19 cases as of 1 October 2020 (collectively representing approximately 85% of the global cases at that time) and (2) specific criteria used to determine eligibility for SARS-CoV-2 diagnostic testing. The implications of inter-country differences on ongoing efforts to understand global disease burden and control the pandemic are also discussed.

Methods

Design

The 25 countries with the highest burden of COVID-19 disease were identified from WHO COVID-19 cumulative case counts as of 1 October 2020.¹⁵ The surveillance case definitions and official testing policies were extracted from official government websites for the respective countries. In instances where definitions were not available on official government websites, definitions were extracted from personal communication with the U.S. Centers for Disease Control and Prevention (CDC) field staff.

To find these data, we searched government websites using the following key words: case definition, suspect case, confirmed case, COVID-19, case criteria, surveillance, testing criteria, guidelines, laboratory, reverse transcriptase-polymerase chain reaction (RT-PCR), and asymptomatic. All surveillance definitions and testing criteria were verified as current as of 1 January 2021. Several of the official policies were not available in English. For these documents, we used Google Translate to identify the definitions and testing policies.

Data management and analysis

In order to compare case definitions across countries, we classified the components of each definition into three parts: (1) diagnostic components including a laboratory test or radiographic imagery; (2) clinical symptoms (such as cough, fever, and Severe Acute Respiratory Infection

(SARI)); and (3) epidemiological criteria, including travel to a high-burden region or contact with a confirmed or suspect case. For each country's testing policy, we considered individuals eligible for diagnostic testing. Countries were classified as testing asymptomatic individuals without any additional criteria, testing asymptomatic individuals with some epidemiological criteria, such as contact with a confirmed case, or recommending testing exclusively for symptomatic individuals. These analyses were based solely on diagnostic testing eligibility criteria and did not consider exceptions, such as testing asymptomatic individuals prior to travel, asymptomatic testing through the private sector, or local-level mass-testing. Elements of national case definitions and testing criteria were compared against global norms from WHO.

Source assessment

To assess sources, we extracted information on their origin and timeliness. The origin was categorized as a government source or personal communication while timeliness was based on date of publication.

Results

Suspect case definitions

We identified suspect case definitions in 24 of 25 countries (96%) (Table 1 and Appendix 1). Israel relies on surveillance via cell phone data; we used these epidemiological criteria from Israel to create a suspect case definition. The three most common criteria included in suspect case definitions were fever, cough, and labored breathing (reported in 92%, 84%, and 84% of 25 countries). Seven countries (28%) used "other" criteria in addition to the common criteria listed in Table 1. The WHO suspected case definition includes clinical symptoms, including the three most common stated above, and epidemiological criteria. Fourteen (56%) countries followed this guidance broadly by including clinical and epidemiological criteria, ten (40%) countries required clinical symptoms alone for the suspect case definition, while two countries (8%) also incorporated diagnostic testing. The United States relies on laboratory evidence, including antibody or antigen positivity, without any clinical symptoms or epidemiological criteria while Colombia primarily relies on epidemiological criteria and clinical symptoms, but includes laboratory and radiological tests as part of their definition to assist with diagnoses.^{16,17}

Probable case definitions

We identified probable case definitions in 16 of 25 countries (64%) (Table 2 and Appendix 2). The WHO probable case definition includes criteria from all three categories, diagnostic testing (chest imagery), clinical symptoms, and epidemiological criteria. 12 out of 16 countries (75%) were consistent with WHO and included criteria from all three categories. There was heterogeneity in the number of required criteria across countries. The three most common criteria included in probable case definitions were fever, labored breathing, and confirmed contact with a probable or confirmed case (reported in 94%, 88%, and 81% of the 16 identified countries, respectively). Fourteen (88%) countries included some type of diagnostic testing for the probable case definition, fifteen (94%) included clinical symptoms in their definitions, and fourteen (88%) included epidemiological criteria.

Confirmed case definitions

We identified confirmed case definitions in all 25 countries (100%) (Table 3 and Appendix 3). All confirmed case definitions required some type of diagnostic testing. Eighteen (72%) countries were consistent with WHO's recommendations and specified RT-PCR tests in their case definition. Of these countries, ten (40%) also included antigen or antibody tests in their definition. Seven countries (28%) did not specify a type of diagnostic test. Seven countries (28%) include reference to their suspect case definition within their confirmed case definition. Of these, three countries (Mexico, Saudi Arabia, and Turkey) require that an individual meet the suspect case definition in addition to diagnostic testing criteria. In addition to confirming cases based on diagnostic testing, six (24%) countries confirmed cases exclusively on loss of taste or smell (anosmia or ageusia). Overall, eight countries (32%) included clinical symptoms as part of their confirmed case definition.

Testing eligibility criteria

We identified testing criteria in all 25 countries (100%) (Appendix 4). Eight (32%) of countries had no symptom requirements for testing, eight (32%) had no symptom requirements for testing but required epidemiological criteria, i.e., exposure to a confirmed or probable case, and nine (36%) countries required symptoms. Of the eight countries requiring epidemiological criteria, five (63%) also allowed asymptomatic testing for a healthcare worker (Appendix 4). Policies

from Saudi Arabia and the United Kingdom specified not to test asymptomatic individuals but included an exception for healthcare employees (Appendix 4). WHO recommends testing asymptomatic individuals who have had contact with a confirmed case; 64% of countries used eligibility criteria at least as permissive as WHO.

Source assessment

92% of case definitions were found on official government websites and 72% were published or included in documents published after the most recent WHO definition was published (7 August 2020) (Table 4). Two countries (India and Pakistan) utilized the previous WHO definition (dated March 2020). We were unable to confirm that these countries updated their definition based on the newest WHO definitions. We were unable to locate definitions on Israel, Iraq, and Iran's government websites. In these countries, we obtained definitions from personnel involved in the respective country's COVID-19 response. 23 of 25 countries (92%) had an official government source for diagnostic testing criteria. Iraq and Iran testing criteria were obtained via personal communication. 88% of testing criteria were published after 1 September 2020. The policies for Philippines, Brazil, and Pakistan were updated in July and August 2020.

Discussion

A consistent statement across all iterations of WHO's global COVID-19 surveillance guidance is that countries may need to adapt the case definitions to their specific circumstances.^{4-6,18} Beginning with the 20 March 2020 version, WHO also encouraged countries to publish their adapted versions online and in periodic situation reports.^{5,6} Nearly all countries (92%) in this analysis indeed chose to deviate from WHO's case definitions in some manner and 92% of countries posted their case definition on an official government website. Suspect and confirmed case classifications were found for nearly all countries, but over a third (36%) excluded the probable case classification. In addition, substantial variation was observed among testing criteria used across the national case definitions. While WHO reserved the use of laboratory testing for confirmed cases only, two countries (8%) included laboratory evidence for suspect cases, 14 countries (88%) for probable cases, and nearly a third (32%) included non-laboratory criteria for confirmed cases. Laboratory evidence in some countries was not restricted to RT-PCR, but rather included increasingly available antigen and antibody tests. Lastly, testing

eligibility criteria also differed widely with many countries either excluding asymptomatic individuals from routine testing (36%) or only including them under certain conditions (32%).

Differences in case definitions and testing eligibility can have important implications on efforts to monitor disease trends and understand the impact of vaccine scale-up efforts across countries and over different time periods. As knowledge of a novel disease increases, the sensitivity and specificity of the case definition changes over time, ultimately impacting the number of cases identified.¹⁹ For example, in 2003 during the earlier SARS epidemic, the Netherlands had several iterations of case definitions that diverged from the prevailing WHO case definition, which was more sensitive and less specific in comparison. When all cases were reevaluated, 21 cases were classified as suspect and two as probable using the latest WHO case definition as opposed to just nine suspect and zero probable cases using the Dutch case definitions.²⁰ As the COVID-19 pandemic emerged in China, a 12 February 2020 case definition change to include clinically diagnosed mild cases resulted in identification of more than 15,000 cases in a single day.²¹ A study of China's successive case definitions, each with gradually increasing sensitivity, also yielded higher detection of cases.¹⁴ From 15 January to 3 March 2020, China's National Health Commission used seven versions of the case definition for COVID-19, estimated to increase the proportion of cases being detected by seven times after the first change, three times from change two to four, and four times after the fifth change. The authors estimated that if the fifth version of the case definition had been applied throughout the outbreak, there would have been 4.2 times more confirmed cases identified in China by 20 February 2020 (232,000 compared to 55,508). These data suggest that use of less sensitive case definitions can underestimate the burden of COVID-19. Changes in case definitions may need to be considered while analyzing an epidemic curve for COVID-19 or other novel diseases.

The wide variation we found in suspect and probable case criteria – and the complete omission of the probable case classification in some nations – is of particular interest. When test results are still pending or tests are unavailable, inclusion of suspected and probable cases allows for early isolation and treatment of these cases.⁷ In addition, in its 7 August 2020 guidance, WHO requested that countries include counts of probable cases along with confirmed cases in weekly

aggregate reports.⁶ WHO indicated that suspected and confirmed case definitions were revised to reflect increased knowledge of the clinical spectrum of COVID-19 signs and symptoms, especially the most common and predictive. These updates were important to informing global and national surveillance because some symptoms have been found to have limited predictive value for surveillance purposes despite their frequent inclusion in case identification procedures.^{22–25}

WHO case definition guidance does not explicitly state the type of test for diagnostic confirmatory testing but references the laboratory guidance that recommends nucleic acid amplification tests (NAAT), such RT-PCR assays.²⁶ Many countries may not have considered the laboratory guidance and used the WHO confirmed case definition verbatim. Indeed, we found that seven of the high burden countries did not specify the type of test to be used in confirmatory testing. Results indicating some countries' use of alternatives to NAAT as laboratory evidence is another important finding. Antigen tests, particularly point of care tests, have been promoted as an important tool for early detection and to prevent asymptomatic spread.⁹ However, their sensitivity is generally lower than NAAT leading to false negatives.²⁷ Antibody tests have typically been recommended as a surveillance assay rather than a standalone diagnostic tool.^{11,28} Despite the limitations of NAAT alternatives, they are increasingly available in many areas and have important benefits, such as lower overall cost, simplified logistics and supply chain management, and faster turnaround of results for rapid versions that may explain their integration in some national confirmed case definitions.

WHO's public health surveillance guidance also includes recommendations for laboratory testing of all suspect and probable cases but acknowledges that testing priorities would be dependent on intensity of transmission, the number of cases, and laboratory capacity. Therefore, guidance was also developed on testing asymptomatic and mildly symptomatic individuals.^{6,26} National differences in testing eligibility criteria may also reflect resource limitations and differences in national health insurance coverage of tests.¹² A number of testing strategies proposed to target segments of the population believed to be at greatest risk of exposure to SARS-CoV-2. For example, some have proposed testing all symptomatic individuals and asymptomatic individuals

with known or suspected contact with COVID-19 case for optimal NAAT testing.^{9,26} Testing asymptomatic individuals without an exposure was suggested if results would impact isolation, quarantine, personal protective equipment usage decisions, surgery eligibility, or inform administration of immunosuppressive therapy.²⁹ In Australia, the national testing policy emphasized defining and targeting high-risk settings, such as residential care facilities or correctional facilities for testing.³⁰ In May 2020, the European Centre for Disease Prevention and Control expanded the pool of individuals eligible for laboratory testing, resources permitting, to include asymptomatic individuals in healthcare settings and long-term care facilities, to identify potential sources of infection and protect vulnerable individuals.¹³

In order to get accurate case counts, detecting both symptomatic and asymptomatic cases is necessary due to the large proportion of COVID-19 cases presenting with no or mild symptoms.²⁹ Inclusion of asymptomatic cases also impacts key epidemiological metrics, such as incidence and the case fatality ratio. While expansive testing criteria will increase the likelihood of capturing asymptomatic infections, they should be balanced against the burden for the public health system in tracing and testing these eligible individuals.³⁰ For example, broadening testing eligibility criteria may overload the healthcare system with individuals with a low probability of infection and/or disease progression. Furthermore, many settings may not have enough resources to test all eligible individuals.²⁹ Although WHO provides harmonious global testing criteria and case definitions, our findings suggest heterogeneity in how these were adapted and that it might be necessary to account for these deviations when comparing COVID-19 case trends across countries.

There are several methodological limitations to our analysis. First, although the included studies represented approximately 85% of the reported cases globally, there may be differences in case definitions among the countries comprising the remaining 15%. Second, although we identified suspect case definitions, confirmed case definitions, and testing criteria for most countries, we only identified probable case definitions in 16. This may be due to the lack of a probable case definition or the lack of making it available in the public domain; regardless, the results of the probable case definition analyses may be less generalizable than the others. Third, since Google

Translate was used to translate definitions not in English, there may have been discrepancies between the original policy intent and what we were able to interpret from the translation. Fourth, our scope was limited to confirmed, probable and suspect case definitions; other classifications, such as persons under investigation, may merit further research. Fifth, after extraction and analyses were completed, additional issues relating to case surveillance have emerged. These include criteria for distinguishing a new case from an existing case, i.e., reinfection cases, as well as the B.1.1.7, 1.351, and P.1 variants of COVID-19.^{16,31–33} Although neither reinfection nor genomic sequencing were part of national case surveillance definitions, reinfection surveillance may provide further information on naturally and vaccine-acquired immunity whilst genomic surveillance may provide further insights on circulating strains and are vital elements of comprehensive national surveillance of COVID-19. Sixth, given the large number of possibilities, we chose not to list every permutation of laboratory, clinical, and epidemiological criteria for the WHO and national suspect, probable, and confirmed case definitions. Finally, despite our analysis of each government’s policies, these policies may not be implemented equally in various settings and may change over time.

Case surveillance remains the foundation for national COVID-19 surveillance and will play a vital role in understanding the impact of national scale-up of vaccines and continued mitigation efforts. There is marked heterogeneity in who is eligible for testing among countries and how countries define a case of COVID-19. Specifically, we observed heterogeneity in elements used across the suspect case definitions (heterogeneity in eligible clinical symptoms), probable case definitions (heterogeneity in laboratory and diagnostic requirements), and confirmed case definitions (with some countries using antigen or PCR and others only used PCR testing). Importantly, testing eligibility criteria varied across countries from being restricted to populations with exposure and symptoms to not having any requirements. Collectively, these issues suggest that efforts to compare trends of COVID-19 across countries require careful interpretation.

Table 1. Suspect case definition criteria across the COVID-19 pandemic’s 25 highest burden countries, current as of 1 January 2021. ‘X’ indicates the criterion was sufficient for, or a potential component of, the suspect case definition requirement(s). Full suspect case definitions can be found in Appendix 1.

Diagnostic Testing		Clinical Symptoms																		Epidemiological Criteria				Other
	Laboratory Evidence*	Cough	Fever	SARI****	Labored Breathing	Headache	Muscle Pain	Throat / Odynophary	Pain / Chest Congestion	Nasal Congestion	Loss of Taste or	Diarrhea	Nausea / Vomiting	Joint Pain	Chills	Rash	SPO ₂ Level****	Conjunctivitis	Fatigue / Weakness	Travel History	Require Hospitaliz	Confirmed Contact	Health Care	Diagnostic /Clinical/Evidence****
WHO Definition † (reference)		X	X	X	X	X	X	X		X		X	X						X	X	X		X	X
Argentina		X	X	X	X	X	X	X			X	X	X							X	X	X	X	X
Bangladesh †		X	X	X	X	X	X	X		X		X	X						X	X	X		X	X
Brazil		X	X	X	X	X		X		X	X	X			X		X							X
Chile		X	X	X	X	X	X	X	X		X	X			X						X			
Colombia	X	X	X		X	X	X	X		X	X	X	X	X		X	X	X	X	X		X	X	X
France‡*		X	X		X	X	X				X	X	X		X				X					
Germany‡*		X	X		X	X	X				X	X	X		X				X					
India ††		X	X	X	X															X	X	X		
Indonesia			X	X	X			X		X										X	X	X		
Iran			X	X									X							X	X			
Iraq†		X	X	X	X	X	X	X		X		X	X						X	X	X		X	X
Israel**																				X		X		
Italy‡*		X	X		X	X	X				X	X	X		X				X					
Mexico		X	X		X	X	X		X	X	X			X	X			X	X					
Pakistan ††		X	X	X	X					X										X	X	X		
Peru		X	X	X	X	X				X														
Philippines †		X	X	X	X	X	X	X		X		X	X						X	X	X		X	X
Russia		X	X		X		X	X	X	X	X	X	X			X	X	X	X					
Saudi Arabia		X	X	X	X	X		X		X	X	X	X								X	X	X	X
South Africa		X	X	X	X		X	X			X	X							X			X		
Spain		X	X	X	X	X	X	X	X		X	X												
Turkey		X	X	X	X	X	X				X	X								X	X	X		
Ukraine		X	X	X	X															X	X	X		
United Kingdom*		X	X								X													

USA	X																							
Total countries including criterion	2	21	23	16	21	15	14	12	4	10	14	15	11	2	6	2	3	3	10	11	10	10	6	7
% of countries***	8%	84%	92 %	64 %	84 %	60%	56%	48 %	16 %	40 %	56 %	60 %	44 %	8%	24 %	8%	12 %	12 %	40%	44%	40 %	40%	24 %	28%
* These countries consider these definitions as "Possible" not "Suspected" cases; because of the comparability between possible and suspect, we treated these definitions as a suspect definition																								
**Israel does not have official surveillance case definitions; individuals are considered suspect based on contact with confirmed cases determined by digital surveillance of cellphones																								
***Refer to Suspected Case Definition for applicable country (Appendix 1)																								
****Severe acute respiratory infection																								
*****Blood oxygen saturation levels																								
†World Health Organization definition (Updated August 2020)																								
††World Health Organization definition (Updated March 2020)																								
‡ European Centres for Disease Control and Prevention Definition																								
***** Denominator is 24 countries with suspect case definition																								

322

Table 2. Probable case definition criteria across the COVID-19 pandemic’s 25 highest burden countries, current as of 1 January 2021. ‘X’ indicates the criterion was sufficient for, or a potential component of, the probable case definition requirement(s). Full probable case definitions can be found in Appendix 2.

	Diagnostic Testing				Clinical Symptoms																	Epidemiological Criteria			Other
	Inconclusive Test	Antigen Test	Antibody Test	Radiographic Imagery	Cough	Fever	SAR ****	Labored Breathing	Headache	Muscle Pain	Sore throat / Odynophagia	Chest Pain / Congestion	Runny nose / Nasal Congestion	Loss of Taste or smell	Diarrhea	Nausea/ Vomiting	Chills	Rash	SPO ₂ Level****	Conjunctivitis	Fatigue / Weakness	Travel History	Require Hospitalization	Confirmed Contact	Diagnostic/ Clinical/ EP ***
WHO Definition (Reference)				X	X	X	X	X	X	X	X		X	X	X	X					X	X	X	X	X
Argentina																									
Bangladesh†				X	X	X	X	X	X	X	X		X	X	X	X					X	X	X	X	X
Brazil																									
Chile	X	X		X	X	X	X	X	X	X	X	X		X	X		X						X	X	X
Colombia	X				X	X		X	X	X	X		X	X	X	X		X	X	X	X	X		X	
France‡				X	X	X		X						X										X	X
Germany‡				X	X	X		X						X										X	X
India ††	X				X	X	X	X														X	X	X	
Indonesia						X	X	X			X		X												X
Iran				X		X	X							X		X						X		X	X
Iraq†				X	X	X	X	X	X	X	X		X	X	X	X					X	X	X	X	X
Israel																									
Italy‡				X	X	X		X						X										X	X
Mexico																									
Pakistan ††	X				X	X	X	X														X	X	X	
Peru																									
Philippines†				X	X	X	X	X	X	X	X		X	X	X	X					X	X	X	X	X
Russia					X	X	X	X	X	X	X	X	X	X				X	X	X	X	X		X	
Saudi Arabia																									
South Africa																									
Spain	X			X	X	X	X	X	X	X	X	X		X	X										

Turkey																									
Ukraine	X																								
United Kingdom																									
USA		X		X	X	X	X	X	X	X	X		X	X	X	X	X				X			X	X
Country Totals	6	2	0	10	13	15	11	14	8	8	9	3	7	12	7	6	2	2	2	2	6	8	6	13	10
% of countries*	38 %	13 %	0 %	63 %	81%	94 %	69 %	88 %	50 %	50 %	56 %	19 %	44%	75 %	44 %	38 %	13 %	13 %	13 %	13 %	38 %	50 %	38%	81 %	63%
***Refer to Probable Case Definition for applicable country (Appendix 2)																									
**** Severe acute respiratory infection																									
*****Blood oxygen saturation levels																									
†World Health Organization definition (Updated August 2020)																									
††World Health Organization definition (Updated March 2020)																									
‡ European Centres for Disease Control and Prevention Definition																									
*Denominator is 16 countries with probable case definition																									

326

Table 3. Confirmed case definition criteria across the COVID-19 pandemic’s 25 highest burden countries, current as of 1 January 2021. ‘X’ indicates the criterion was sufficient for, or a potential component of, the confirmed case definition requirement(s). Full confirmed case definitions can be found in Appendix 3.

	Diagnostic Testing					Clinical Symptoms					Epidemiological Criteria			Other*
	PCR Test	Antigen Test	Antibody Test	Positive Test (non-specified)	Radiographic Imagery	Meet Suspect Case Definition	Cough	Fever	SARI**	Loss of taste or smell	Travel History	Require Hospitalization	Confirmed Contact	Diagnostic/Clinical/ EPI
WHO Definition (Reference)	X													
Argentina	X	X				X	X	X		X			X	X
Bangladesh†	X													
Brazil	X	X	X		X				X	X			X	X
Chile	X					X				X		X		
Colombia	X	X												
France‡	X	X												
Germany‡	X	X												
India †				X										
Indonesia	X													
Iran				X										
Iraq†	X													
Israel				X										
Italy‡	X	X												
Mexico				X		X				X			X	
Pakistan †				X										
Peru	X	X				X					X	X	X	
Philippines†	X	X												
Russia	X	X	X											
Saudi Arabia	X					X					X	X	X	
South Africa	X													
Spain	X	X				X				X				
Turkey	X					X				X	X	X	X	
Ukraine				X										

United Kingdom				X										
USA	X													
Totals	18	10	2	7	1	7	1	1	1	6	3	4	6	2
% of countries**	72%	40%	8%	28%	4%	28%	4%	4%	4%	24%	12%	16%	24%	8%
†World Health Organization definition (confirmed case definition remained the same as the March definition for the August 2020 update)														
‡ European Centres for Disease Control and Prevention Definition														
*Other criteria included in the Confirmed case definition														
** Denominator is 25 countries with confirmed case definitions														
*** Severe acute respiratory infection														

Table 4. Assessment of sources for case definition and testing criteria across the COVID-19 pandemic's 25 highest burden countries, current as of 1 January 2021.

Countries	Case Definition Source (Date)*	Testing Criteria Source (Date)*
WHO	WHO ⁶ (8/7/2020)	N/A
Argentina	Government ³⁴ (9/11/2020)	Government ³⁵ (9/23/2020)
Bangladesh	Government ³⁶ (11/5/2020)	Government ³⁶ (11/5/2020)
Brazil	Government ³⁷ (8/5/2020)	Government ³⁷ (8/5/2020)
Chile	Government ³⁸ (10/1/2020)	Government ³⁹ (11/18/2020)***
Colombia	Government ¹⁷ (10/19/2020)	Government ⁴⁰ (10/2020)
France	ECDC ⁴¹ (12/3/2020)	Government ⁴² (10/19/2020)***
Germany	ECDC ⁴¹ (12/3/2020)	Government ⁴³ (12/16/2020)
India	Government ⁴⁴ (7/3/2020)	Government ⁴⁵ (9/4/2020)
Indonesia	Government ⁴⁶ (7/13/2020)	Government ⁴⁷ (1/1/2021)**
Iran	CDC contact ⁴⁸ (9/29/2020)*	CDC contact ⁴⁸ (9/29/2020)*
Iraq	CDC contact ⁴⁹ (10/2/2020)*	CDC contact ⁴⁹ (10/2/2020)*
Israel	CDC contact ⁵⁰ (10/7/2020)*	Government ⁵¹ (12/17/2020)
Italy	ECDC ⁴¹ (12/3/2020)	Government ⁵² 10/23/2020)
Mexico	Government ^{53,54} (8/25/2020)	Government ⁵⁵ (11/11/2020)
Pakistan	Government ⁵⁶ (3/27/2020)	Government ^{57,58} (12/2/2020)
Peru	Government ⁵⁹ (7/10/2020)	Government ⁶⁰ (9/30/2020)
Philippines	Government ⁶¹ (11/25/2020)	Government ⁶² (7/6/2020)
Russia	Government ⁶³ (10/26/2020)	Government ⁶⁴ (1/1/2021)**
Saudi Arabia	Government ⁶⁵ (10/2020)	Government ⁶⁵ (10/2020)
South Africa	Government ⁶⁶ (8/18/2020)	Government ⁶⁷ (9/16/2020)
Spain	Government ⁶⁸ (12/18/2020)	Government ⁶⁸ (12/18/2020)
Turkey	Government ⁶⁹ (12/7/2020)	Government ⁶⁹ (12/7/2020)
Ukraine	Government ⁷⁰ (3/28/2020)	Government ⁷¹ (1/1/2021)**
UK	Government ⁷² (9/28/2020)	Government ⁷³ (1/1/2021)**
USA	Government ¹⁶ (8/5/2020)	Government ⁸ (10/21/2020)

* Date of U.S. Centers for Disease Control and Prevention (CDC) contact communication

**Date the source website was last verified in absence of website update date

*** Date the website was last updated

References

- 1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727–33.
- 2 National Health Commission of the People’s Republic of China. Update on the novel coronavirus pneumonia outbreak. http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml.
- 3 World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). [https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)).
- 4 World Health Organization. Global Surveillance for human infection with novel coronavirus (2019-nCoV): interim guidance, 31 January 2020. 2020. <https://apps.who.int/iris/handle/10665/330857> (accessed Dec 13, 2020).
- 5 World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020. 2020. <https://apps.who.int/iris/handle/10665/331506> (accessed Dec 13, 2020).
- 6 World Health Organization. Public health surveillance for COVID-19: interim guidance, 7 August 2020. 2020. <https://apps.who.int/iris/handle/10665/333752> (accessed Dec 13, 2020).
- 7 Koh D, Cunningham AC. Counting Coronavirus Disease-2019 (COVID-19) Cases: Case Definitions, Screened Populations and Testing Techniques Matter. 2020; **49**: 5.
- 8 Overview of Testing for SARS-CoV-2 (COVID-19). 2020; published online Oct 21. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>.
- 9 Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. *N Engl J Med* 2020; **383**: e120.
- 10 Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study - The Lancet. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30411-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30411-6/fulltext) (accessed Dec 16, 2020).
- 11 Cheng MP, Papenburg J, Desjardins M, *et al.* Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2. *Ann Intern Med* 2020; **172**: 726–34.
- 12 Atsawarungrangkit A, Yuan J, Kodama T, *et al.* Evolving global and national criteria for identifying a suspected case of COVID-19. *J Int Med Res* 2020; **48**: 0300060520938943.
- 13 Peralta-Santos A. Assessment of COVID-19 surveillance case definitions and data reporting in the European Union. ; : 7.

- 368 14Tsang TK, Wu P, Lin Y, Lau EHY, Leung GM, Cowling BJ. Effect of changing case
369 definitions for COVID-19 on the epidemic curve and transmission parameters in mainland
370 China: a modelling study. *Lancet Public Health* 2020; 5: e289–96.
- 371 15WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int> (accessed Jan 29,
372 2021).
- 373 16Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5,
374 2020. 2020; published online Aug 5. [https://wwwn.cdc.gov/nndss/conditions/coronavirus-](https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/)
375 [disease-2019-covid-19/case-definition/2020/08/05/](https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/) (accessed Oct 13, 2020).
- 376 17Por el cual se optimiza el Programa de Pruebas, Rastreo y Aislamiento Selectivo Sostenible -
377 PRASS, para el monitoreo y seguimiento de casos y contactos de COVID - 19 en Colombia.
378 Colombia: Republic of Colombia, 2020.
- 379 18World Health Organization. Global surveillance for COVID-19 disease caused by human
380 infection with novel coronavirus (COVID-19): interim guidance, 27 February 2020. 2020.
381 <https://apps.who.int/iris/handle/10665/331231> (accessed Dec 13, 2020).
- 382 19Teutsch S. Considerations in Planning a Surveillance System. In: Principles & Practice of
383 Public Health Surveillance. Oxford: Oxford University Press, 2010: 18–30.
- 384 20Timen A, van Doornum GJJ, Schutten M, *et al.* Public health implications of using various
385 case definitions in The Netherlands during the worldwide SARS outbreak. *Clin Microbiol*
386 *Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2006; 12: 1214–20.
- 387 21Wu P, Hao X, Lau EHY, *et al.* Real-time tentative assessment of the epidemiological
388 characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. *Euro*
389 *Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull* 2020; 25. DOI:10.2807/1560-
390 7917.ES.2020.25.3.2000044.
- 391 22Dawson P, Rabold EM, Laws RL, *et al.* Loss of Taste and Smell as Distinguishing Symptoms
392 of Coronavirus Disease 2019. *Clin Infect Dis* 2020; published online June 21.
393 DOI:10.1093/cid/ciaa799.
- 394 23Haehner A, Draf J, Dräger S, de With K, Hummel T. Predictive Value of Sudden Olfactory
395 Loss in the Diagnosis of COVID-19. *ORL* 2020; 82: 175–80.
- 396 24Roland LT, Gurrola JG, Loftus PA, Cheung SW, Chang JL. Smell and taste symptom-based
397 predictive model for COVID-19 diagnosis. *Int Forum Allergy Rhinol* 2020; 10: 832–8.
- 398 25Yamamoto-Moreno JA, Pineda-Aguilar C, Ruiz-Pérez S, Gortarez-Quintana GL, Ruiz-Dorado
399 MA. Effectiveness of COVID-19 case definition in identifying SARS-CoV-2 infection in
400 northern Mexico. *Popul Med* 2020; 2: 1–8.
- 401 26Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020;
402 published online March 19. <https://www.who.int/publications/i/item/10665-331501> (accessed
403 Dec 18, 2020).

- 27 CDC. Information for Laboratories about Coronavirus (COVID-19). Cent. Dis. Control Prev. 2020; published online Feb 11. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html> (accessed Dec 18, 2020).
- 28 Krajewski R, Gołębiowska J, Makuch S, Mazur G, Agrawal S. Update on serologic testing in COVID-19. *Clin Chim Acta* 2020; **510**: 746–50.
- 29 Hanson KE, Caliendo AM, Arias CA, *et al*. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. 2020; : 70.
- 30 McArthur L, Sakthivel D, Ataide R, Chan F, Richards JS, Narh CA. Review of Burden, Clinical Definitions, and Management of COVID-19 Cases. *Am J Trop Med Hyg* 2020; **103**: 625–38.
- 31 Interim guidelines for detecting cases of reinfection by SARS-CoV-2 - PAHO/WHO | Pan American Health Organization. <https://www.paho.org/en/documents/interim-guidelines-detecting-cases-reinfection-sars-cov-2> (accessed Dec 18, 2020).
- 32 Reinfection with SARS-CoV: considerations for public health response. 2020; published online Sept 21. <https://www.ecdc.europa.eu/sites/default/files/documents/Re-infection-and-viral-shedding-threat-assessment-brief.pdf> (accessed Dec 18, 2020).
- 33 WHO | SARS-CoV-2 Variants. WHO. <http://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/> (accessed Jan 29, 2021).
- 34 Definición de caso. 2020; published online Sept 11. <https://www.argentina.gob.ar/salud/coronavirus-COVID-19/definicion-de-caso> (accessed Jan 4, 2020).
- 35 Consenso sobre el uso de pruebas diagnósticas para SARS-CoV-2. Argentina, 2020.
- 36 Ferdousi S. National Guidelines of Clinical Management of Coronavirus Disease 2019 (Covid-19). Government of the People’s Republic of Bangladesh, 2020.
- 37 Guia de Vigilância Epidemiológica Emergência de Saúde Pública de Importância Nacional pela Doença pelo Coronavírus 2019. Government of Brazil, 2020.
- 38 Actualización de definición de caso sospechoso, confirmado y probable para vigilancia epidemiológica ante pandemia de COVID-19. Government of Chile, 2020 <https://www.minsal.cl/wp-content/uploads/2020/10/201006-Definici%C3%B3n-de-caso-sospechoso.pdf> (accessed Jan 4, 2020).
- 39 Plan de Acción por Coronavirus. 2020; published online Nov 18. <https://www.gob.cl/coronavirus/plandeaccion#salud/> (accessed Nov 30, 2020).
- 40 ABECÉ Programa de Pruebas, Rastreo y Aislamiento Selectivo Sostenible – PRASS. 2020; published online Oct.

- 438 [https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/VSP/abece-](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/VSP/abece-prass.pdf)
- 439 [prass.pdf](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/VSP/abece-prass.pdf).
- 440 41 Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. 2020;
- 441 published online May 29. [https://www.ecdc.europa.eu/en/covid-19/surveillance/case-](https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition)
- 442 [definition](https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition) (accessed Sept 16, 2020).
- 443 42 Dépistage : les réponses à vos questions. 2020; published online Oct 19. [https://solidarites-](https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-la-covid-19/article/depistage-les-reponses-a-vos-questions)
- 444 [sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-la-](https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-la-covid-19/article/depistage-les-reponses-a-vos-questions)
- 445 [covid-19/article/depistage-les-reponses-a-vos-questions](https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-la-covid-19/article/depistage-les-reponses-a-vos-questions) (accessed Dec 3, 2020).
- 446 43 Die nationale Teststrategie. 2020; published online Dec 16.
- 447 <https://www.zusammengengencorona.de/informieren/die-nationale-teststrategie/> (accessed Jan
- 448 5, 2020).
- 449 44 Clinical Management Protocol: COVID-19. Government of India, 2020.
- 450 45 Advisory on Strategy for COVID-19 Testing in India. 2020; published online Sept 4.
- 451 <https://www.mohfw.gov.in/pdf/AdvisoryonstrategyforCOVID19TestinginIndia.pdf> (accessed
- 452 Nov 25, 2020).
- 453 46 Pedoman Pencegahan Dan Pengendalian Coronavirus Disease 2019 (COVID-19). Republic of
- 454 Indonesia, 2020.
- 455 47 Tanya Jawab. 2020. <https://covid19.go.id/tanya-jawab?page=2> (accessed Dec 3, 2020).
- 456 48 Farag N. Case definitions and testing criteria question. 2020; published online Sept 29.
- 457 49 Majeed YY. Seeking COVID-19 surveillance case definitions and testing criteria. 2020;
- 458 published online Oct 2.
- 459 50 Burke H. Case definitions and testing criteria question. 2020; published online Oct 7.
- 460 51 Testing for COVID-19. 2020; published online Dec 17.
- 461 <https://www.gov.il/en/Departments/General/corona-tests> (accessed Jan 4, 2020).
- 462 52 Test di laboratorio per SARS-CoV-2 e loro uso in sanità pubblica. Government of Italy, 2020
- 463 [https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=76980](https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=76980&parte=1%20&serie=null)
- 464 [&parte=1%20&serie=null](https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=76980&parte=1%20&serie=null).
- 465 53 Dirección General de Epidemiología. Actualización de la Definición Operacional de Caso
- 466 Sospechoso de Enfermedad Respiratoria Viral. Government of Mexico, 2020
- 467 https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospec
- 468 [hoso_ERV_240820.pdf](https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospec) (accessed Sept 16, 2020).
- 469 54 Bastidas DrMA. Lineamiento Estandarizado Para La Vigilancia Epidemiológica Y Por
- 470 Laboratorio De La Enfermedad Respiratoria Viral. Government of Mexico, 2020
- 471 <https://coronavirus.gob.mx/wp->

- 472 content/uploads/2020/09/Lineamiento_VE_y_Lab_Enf_Viral_Ago-2020.pdf (accessed Jan 4,
473 2020).
- 474 55Zegarra JLA. Comunicado emergente sobre el uso de pruebas para la detección de antígeno
475 SARS-CoV-2 en México. Government of Mexico, 2020 [https://coronavirus.gob.mx/wp-](https://coronavirus.gob.mx/wp-content/uploads/2020/11/Prueba_antigenica_COVID_11Nov2020.pdf)
476 content/uploads/2020/11/Prueba_antigenica_COVID_11Nov2020.pdf (accessed Dec 3, 2020).
- 477 56Case Definition for COVID-19. Islamabad: Islamic Republic of Pakistan, 2020
478 <https://www.nih.org.pk/wp-content/uploads/2020/03/Case-Definition-for-COVID-19.pdf>
479 (accessed Nov 27, 2020).
- 480 57National Testing Guidelines Real-Time Polymerase Chain Reaction (RT-PCR) Diagnostic
481 Test. Islamic Republic of Pakistan, 2020.
- 482 58Ministry of National Health Services. Testing Strategy Incorporating COVID-19 Antigen
483 Detection Rapid Diagnostic Tests (Ag-RDT). Islamic Republic of Pakistan, 2020
484 [https://storage.covid.gov.pk/new_guidelines/02December2020_20201202_TESTING_STR-](https://storage.covid.gov.pk/new_guidelines/02December2020_20201202_TESTING_STRATEGY_INCORPORATING_COVID-19_ANTIGEN_DETECTION_RAPID_DIAGNOSTIC_TESTS_(Ag-RDT)_5302.pdf)
485 TEGY_INCORPORATING_COVID-
486 19_ANTIGEN_DETECTION_RAPID_DIAGNOSTIC_TESTS_(Ag-RDT)_5302.pdf
487 (accessed Jan 5, 2020).
- 488 59Alerta epidemiológica ante riesgo de intensificación de la transmisión comunitaria de
489 COVID-19 en el periodo post cuarentena, en el Perú. Government of Peru, 2020
490 <https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf> (accessed Jan 4, 2020).
- 491 60Alerta epidemiológica para la aplicación de pruebas diagnósticas en casos de COVID-19 en el
492 Perú. Government of Peru [https://www.dge.gob.pe/portalnuevo/publicaciones/alertas-](https://www.dge.gob.pe/portalnuevo/publicaciones/alertas-epidemiologicas/)
493 epidemiologicas/ (accessed Sept 30, 2020).
- 494 61Further Amendment to Administrative Order No. 2020-0013 dated 09 April 2020 entitled,
495 “Revised Administrative Order No. 2020-0012, ‘Guidelines for the Implementation for the
496 Inclusion of the Coronavirus Disease 2019 (COVID-19) in the list of Notifiable Diseases for
497 Mandatory Reporting to the Department of Health’ dated March 17, 2020.” Republic of the
498 Phillipines, 2020 <https://doh.gov.ph/sites/default/files/health-update/ao2020-0013-B.pdf>
499 (accessed Jan 4, 2020).
- 500 62Duque III FT, III FTD. Amendment to Department Memorandum No. 2020-0258 entitled
501 Updated Interim Guidelines on Expanded Testing for COVID-19. Republic of the Philippines,
502 2020 <https://www.doh.gov.ph/sites/default/files/health-update/dm2020-0258-A.pdf>.
- 503 63Vremennyye Metodicheskiye Rekomendatsii Profilaktika, Diagnostika I Lecheniye Novoy
504 Koronavirusnoy Infektsii (COVID-19). Russian Federation, 2020.
- 505 64Chasto Zadavayemyye Voprosy. 2020. <https://xn--80aesfpebagmfb1c0a.xn--p1ai/faq/?tags=39>
506 (accessed Nov 30, 2020).
- 507 65COVID-19 Coronavirus Disease Guidelines. the Kingdom of Saudi Arabia, 2020.

- 508 66Coronavirus disease 2019 (COVID-19) caused by a Novel Coronavirus (SARS-CoV-2).
509 Republic of South Africa, 2020.
- 510 67Ramaphosa C. Statement by President Cyril Ramaphosa on Progress in the National Effort to
511 Contain the COVID-19 Pandemic. 2020; published online Sept 16.
512 [https://sacoronavirus.co.za/2020/09/16/statement-by-president-cyril-ramaphosa-on-progress-](https://sacoronavirus.co.za/2020/09/16/statement-by-president-cyril-ramaphosa-on-progress-in-the-national-effort-to-contain-the-covid-19-pandemic-3/)
513 [in-the-national-effort-to-contain-the-covid-19-pandemic-3/](https://sacoronavirus.co.za/2020/09/16/statement-by-president-cyril-ramaphosa-on-progress-in-the-national-effort-to-contain-the-covid-19-pandemic-3/).
- 514 68Estrategia de Detección Precoz, Vigilancia y Control de Covid-19. Government of Spain,
515 2020.
- 516 69T.R. Ministry of Health. COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel Bilgiler,
517 Epidemioloji Ve Tani. Ankara: Republic of Turkey, 2020.
- 518 70Informatsiyini materialy na osnovi Standartiv medychnoyi dopomohy Koronavirusna khvoroba
519 COVID-19. 2020; published online June 16.
- 520 71Coronavirus in Ukraine. <https://covid19.gov.ua/en> (accessed Dec 8, 2020).
- 521 72COVID-19: investigation and initial clinical management of possible cases. 2020; published
522 online Oct 2. [https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection)
523 [investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection)
524 [cases-of-wuhan-novel-coronavirus-wn-cov-infection](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection) (accessed Nov 25, 2020).
- 525 73Getting tested for coronavirus (COVID-19). [https://www.gov.uk/getting-tested-for-](https://www.gov.uk/getting-tested-for-coronavirus)
526 [coronavirus](https://www.gov.uk/getting-tested-for-coronavirus) (accessed Nov 30, 2020).
- 527
- 528

529 Appendix 1. Suspect Definitions

Country	Definition
WHO	1. A person who meets the clinical AND epidemiological criteria: Clinical Criteria: Acute onset of fever AND cough; OR Acute onset of any three or more of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status Epidemiological Criteria: Residing or working in an area with high risk of transmission of virus: closed residential settings, humanitarian settings such as camp and camp-like settings for displaced persons; anytime within the 14 days prior to symptom onset; OR Residing or travel to an area with community transmission anytime within the 14 days prior to symptom onset; OR Working in any health care setting, including within health facilities or within the community; anytime within the 14 days prior to symptom onset.
Iraq†	
Bangladesh†	
Philippines†	2. A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured fever of $\geq 38^{\circ}\text{C}$; and cough; with onset within the last 10 days; and requires hospitalization)
India	1. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset.
Pakistan	2. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset 3. A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g. cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.
USA	Meets supportive laboratory evidence with no prior history of being a confirmed or probable case. Supportive Lab evidence: Detection of specific antibody in serum, plasma, or whole blood. Detection of specific antigen by immunocytochemistry in an autopsy specimen
Italy*‡	
Germany*‡	Any person meeting clinical criteria: at least one of the following symptoms: cough, fever, shortness of breath, sudden onset of anosmia, ageusia or dysgeusia. Additional less specific symptoms may include headache, chills, muscle pain, fatigue, vomiting and/or diarrhea
France*‡	
Brazil	1. Individual with acute respiratory condition, characterized by at least two (2) of the following signs and symptoms: fever (even if referred), chills, sore throat, headache, cough, runny nose, olfactory disorders or taste disorders. In children in addition to the previous items, nasal obstruction is also considered, in the absence of another specific diagnosis. In the elderly specific aggravation criteria such as syncope, mental confusion, excessive sleepiness, irritability and inappetence should also be considered. If COVID-19 is suspected, fever may be absent and gastrointestinal symptoms (diarrhea) may be present. 2. Individual with Influenza like illness who has: dyspnea / respiratory discomfort Or persistent pressure in the chest Or O_2 saturation less than 95% in room air Or bluish color of the lips or face. In children in addition to the previous items, observe the flapping of the nose, cyanosis, intercostal circulation, dehydration and lack of appetite.
Russia	Clinical manifestations of acute respiratory infection (ARI) (temperature above 37.5°C and one or more of the following: cough - dry or with scanty sputum, shortness of breath, feeling of congestion in the chest, satiety blood oxygen according to pulse oximetry (SpO_2) $\leq 95\%$, sore throat, nasal congestion or mild rhinorrhea, impaired or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin rash) in the absence of other known causes, which explain the clinical picture regardless of the epidemiological anamnesis.
Colombia	Person with exposure due to having been in a place with community transmission or endemic or outbreak or to probable cases, and with respiratory OR non-respiratory clinical manifestations of COVID-19, of any severity, clinical laboratory findings or radiological, belonging to groups of risk factors or vulnerability. Also asymptomatic individuals with exposure to probable or confirmed COVID-19 cases. Respiratory clinical manifestations: fever greater than 38°C , cough, fatigue, expectoration, shortness of breath / dyspnea, sore throat, rhinorrhea, $\text{SpO}_2 < 93\%$. Non-respiratory clinical manifestations: anosmia, hyposmia, ageusia, dysgeusia, diarrhea, anorexia, nausea and vomiting, abdominal pain or discomfort, acute conjunctivitis, seizures, vertigo, headache, myalgia, skeletal muscle injuries, altered consciousness, acute cerebrovascular disease, ataxia, seizures, meningoencephalitis, Guillain-Barre syndrome, mental status disorders, hepatic compromise due to elevated aminotransferases, erythematous rash, hive rash, vesicles, acral ischemia, unilateral transient livedo reticularis, acute cardiac injury, heart failure arrhythmia, shock, acute myocarditis, chest tightness, acute kidney injury, urinary symptoms / cystitis, coagulation disorders, thrombotic events, antiphospholipid antibodies, hearing loss or hearing discomfort Clinical Laboratory and Radiological findings: Laboratory and non-etiological clinical diagnostic tests: Albumin Decrease (81%), CRP increase (79%) (MIS-C 94%), LDH increased (69.3%), Thrombocytosis (61%), Lymphopenia (57.5%, 25%, 56.5%), Interleukin 6 increased (56%), AST increase (37%), Leukopenia (28%, 25%), Leukocytosis (18.3%), Neutrophilia (MIS-C 83%), Thrombocytopenia (13%, 16.4-32.3%), Increase in D-dimer, Ferritin, Decrease in T3 and T4 Troponin T (MIS-C 68%), pro BNP (MIS-C 77%). Pulmonary radiological findings Bilateral commitment (81%), Consolidation (73.5%), Ground Glass Opacity (73.5%), Abnormal echocardiogram (MIS-C 59%, 63%). Factors of Vulnerability: Health workers, Workers who serve in high volumes of public work in social protection, workers with high mobility due to occupational activity and internal Colombia migrants.
Peru	Person with Acute Respiratory Infection, who presents cough or pain from throat and at least one or more of the following signs / symptoms: General discomfort, Fever, Headache, Difficulty breathing, Nasal congestion.

Argentina	1. Anyone (of any age) who has two or more of the following symptoms: Fever (37.5 ° C or more), Cough, Odynophagia, Shortness of breath, Headache, Myalgia, Diarrhea / vomiting, No other etiology that fully explains the clinical presentation. This criterion includes any severe acute respiratory infection 2. Sudden loss of taste or smell, in the absence of any other identified cause 3. Anyone who is a health worker, resides or works in closed or long-term institutions, is essential personnel, lives in popular neighborhoods or native towns, or had close contact of confirmed COVID-19 case, that within 14 days of contact AND has 1 or more of these symptoms: fever (37.5 ° C or higher), cough, odynophagia, shortness of breath, sudden loss of taste or smell.
Spain	Anyone with a clinical picture of acute respiratory infection of onset sudden of any severity that occurs, among others, with fever, cough or feeling of shortness of breath. Other symptoms such as odynophagia, anosmia, ageusia, muscle pain, diarrhea, chest pain or headache, among others may also be considered symptoms of suspected SARS-CoV-2 infection according to clinical judgment.
Mexico	Person of any age who has had at least one of the following signs and symptoms in the last 10 days: cough, fever, dyspnea (serious condition) or headache. In children under five years of age, irritability can replace headache. Accompanied by at least one of the following minor signs or symptoms: Myalgia, Arthralgias, Odynophagia, Chills, chest pain, Rhinorrhea, Anosmia, dysgeusia, Conjunctivitis.
South Africa	Any person presenting with an acute (≤ 10 days) respiratory tract infection or other clinical illness compatible with COVID-19, or an asymptomatic person who is a close contact of a confirmed case. Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell) or dysgeusia (alteration of the sense of taste), with or without other symptoms (which may include fever, weakness, myalgia, or diarrhea)
United Kingdom*	New continuous cough or temperature $\geq 37.8^{\circ}\text{C}$ or loss of, or change in, normal sense of smell (anosmia) or taste (ageusia)
Iran	1. Acute onset of fever OR Acute onset of ILI/ARI symptoms / nausea and vomiting AND epidemiological criteria (residing/working/travel to high-risk settings or community transmission or health facilities within 14 days) 2. SARI
Chile	1. Patient presenting an acute picture with at least two of the symptoms compatible with Covid-19: fever (37.8 ° C or higher), cough, dyspnea, chest pain, odynophagia, myalgia, chills, headache, diarrhea, or sudden loss or decrease of smell (anosmia or hyposmia) or taste (ageusia or dysgeusia) 2. Patient with severe acute respiratory infection (requiring hospitalization).
Saudi Arabia	1. Patient with acute respiratory illness (sudden onset of at least one of the following: fever (measured or by history), cough, or shortness of breath) 2. Patient with sudden onset of at least one of the following: headache, sore throat, rhinorrhea, nausea, diarrhea or loss of smell or taste. AND in the 14 days prior to symptom onset, met at least one of the following criteria Had contact with a confirmed COVID-19 case Or Working in or attended a healthcare facility where patients with confirmed COVID-19 were admitted. 3. Any admitted Adult patient with unexplained severe acute respiratory illness (SARI), either Community Acquired Pneumonia (CAP) or Hospital Acquired Pneumonia (HAP).
Turkey*	1. At least one of the following signs and symptoms: fever, cough, shortness of breath, sore throat, headache, muscle aches, loss of taste and smell, diarrhea AND The clinical picture cannot be explained by another cause / disease AND one of the following within 14 days before the onset of symptoms: he or close contact has history of being in a high-risk area for the disease or he has confirmed contact with a COVID-19 case. 2. At least one of the signs and symptoms of fever and SARI (cough and respiratory distress), requiring hospitalization and the clinical picture cannot be explained by another cause / disease. SARI: The need for hospitalization due to fever, cough and dyspnea, tachypnea, hypoxemia, hypotension, diffuse radiological findings on lung imaging and change in consciousness in a patient with acute respiratory tract infection that developed in the last 14 days 3. Combination of at least two of the following signs and symptoms: fever, cough, shortness of breath, sore throat, headache, muscle aches, loss of taste and smell or diarrhea, and this situation cannot be explained by another cause / disease.
Indonesia	1. A person who has one of the following criteria: People with Acute Respiratory Infections (ARI) (namely fever ($\geq 38.0^{\circ}\text{C}$) or a history of fever; and accompanied by any of the symptoms / signs of respiratory disease such as: cough / shortness of breath / sore throat / runny nose / pneumonia from mild to severe) * AND in the last 14 days before symptoms appeared had a history travel or live in a country / territory of Indonesia reporting local transmissions 2. People with any of the symptoms / signs of ARI AND in the last 14 days before symptoms develop had a history of contact with a confirmed / probable COVID-19 case. 3. People with severe ARD / severe pneumonia requiring hospitalization AND no other cause based on a convincing clinical picture.
Israel	Israel does not have official surveillance case definitions; individuals are considered suspect based on contact with confirmed cases determined by digital surveillance of cellphones
Ukraine	1. A patient with acute respiratory illness (sudden onset, fever, and at least one of the following symptoms: cough or difficulty breathing), regardless of the need for hospitalization, and who 14 days before the onset of symptoms meets at least one of the following epidemiological criteria: Had contact with a confirmed or probable case of COVID-19 or visited or resided in a country / region with local transmission of the virus in the community according to WHO situation reports. 2. Patient with severe acute respiratory disease (body temperature $\geq 38^{\circ}\text{C}$ and at least one of the following symptoms: cough or difficulty breathing), and the need for hospitalization and the absence of other reasons that fully explain the clinical picture.

* These countries use a "Possible" case definition in place of a "Suspected" case definition

†World Health Organization Definition

‡ European Centres for Disease Control and Prevention Definition

530

531

532 Appendix 2. Probable Definitions

Country	Definition
WHO Definition	1. A patient who meets clinical criteria above AND is a contact of a probable or confirmed case, or epidemiologically linked to a cluster with at least one confirmed case 2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease Typical chest imaging findings suggestive of COVID-19 include the following chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution; chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution; lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative patterns with or without air bronchograms. 3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause 4. Death, not otherwise explained, in an adult with respiratory distress preceding death AND was a contact of a probable or confirmed case or epidemiologically linked to a cluster with at least one confirmed case.
Iraq†	
Bangladesh†	
Philippines†	
India	1. A suspect case for whom testing for the COVID-19 virus is inconclusive.
Pakistan	2. A suspect case for whom testing could not be performed for any reason.
USA	1. Meets clinical criteria AND epidemiologic evidence with no confirmatory laboratory testing performed for COVID-19 2. Meets presumptive laboratory evidence (Detection of SARS-CoV-2 by antigen test in a respiratory specimen) 3. Meets vital records criteria with no confirmatory laboratory evidence Clinical Criteria: At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion or runny nose OR At least one of the following symptoms: cough, shortness of breath, difficulty breathing, new olfactory disorder, new taste disorder OR Severe respiratory illness with at least one of the following: Clinical or radiographic evidence of pneumonia, Acute respiratory distress syndrome (ARDS). Epi Criteria: One or more of the following exposures in the prior 14 days: Close contact with a confirmed or probable case of COVID-19 disease; OR Member of a risk cohort as defined by public health authorities during an outbreak.
Italy‡	
Germany‡	Any person meeting clinical criteria (at least one of the following symptoms: cough, fever, shortness of breath, sudden onset of anosmia, ageusia or dysgeusia) with Epi link (Close contact with confirmed case within 14 days prior to onset or having been a resident or staff in an institution with ongoing transmission within 14 days prior to onset) OR Any person meeting diagnostic criteria (Radiological evidence showing lesions compatible with COVID-19)
France‡	
Brazil	No Probable case definition
Russia	Same as Suspected case AND at least one of the epidemiological signs is present: Return from a foreign trip 14 days before the onset of symptoms; Having close contact in the last 14 days with a person under monitoring for COVID-19, which subsequently fell ill; Having close contact in the last 14 days with a person who laboratory confirmed diagnosis of COVID-19; Availability of professional contacts with persons who have been identified a suspected or confirmed case of COVID-19.
Colombia	Person with any type of individual or multiple exposure to confirmed cases and with respiratory or non-respiratory clinical manifestations of COVID-19, of any severity and clinical or radiological laboratory findings. It also includes the person with doubtful etiological laboratory results (RT-PCR) or laboratory testing is not feasible for some reason Respiratory clinical manifestations: fever greater than 38°C, cough, fatigue, expectoration, shortness of breath / dyspnea, sore throat, rhinorrhea, SpO₂ <93% Non-respiratory clinical manifestations: anosmia, hyposmia, ageusia, dysgeusia, diarrhea, anorexia, nausea and vomiting, abdominal pain or discomfort, acute conjunctivitis, seizures, vertigo, headache, myalgia, skeletal muscle injuries, altered consciousness, acute cerebrovascular disease, ataxia, seizures, meningoencephalitis, Guillain-Barre syndrome, mental status disorders, hepatic compromise due to elevated aminotransferases, erythematous rash, hive rash, vesicles, acral ischemia, unilateral transient livedo reticularis, acute cardiac injury, heart failure arrhythmia, shock, acute myocarditis, chest tightness, acute kidney injury, urinary symptoms / cystitis, coagulation disorders, thrombotic events, antiphospholipid antibodies, hearing loss or hearing discomfort
Peru	No Probable case definition
Argentina	No Probable case definition
Spain	1. Person with severe acute respiratory infection with clinical and radiological symptoms compatible with COVID-19 and negative diagnostic test results, or suspected cases with inconclusive diagnostic test. 2. Cases with high clinical-epidemiological suspicion with repeatedly negative diagnostic test (at least one PCR) and positive serology for SARS-CoV-2 performed by high-throughput serological techniques.
Mexico	No Probable case definition
South Africa	No Probable case definition
United Kingdom	No Probable case definition
Iran	1. Suspect case AND close contact with probable/confirmed case 2. Suspect case AND positive imaging 3. Acute onset of Anosmia/ageusia without identified cause 4. Death of a Suspect Case

Chile	1. Probable case by laboratory result: patient who meets the definition of a suspected case in which the PCR result is indeterminate or has a positive antigenic test for SARS-CoV-2. 2. Probable case due to epidemiological link: person who has been in close contact with a confirmed case and develops fever (axillary temperature ~ 37.8) or at least two symptoms compatible with COVID-19 within 14 days of contact. The probable case due to an epidemiological link does not require an RT-PCR test for SARS-CoV-2. If for any reason, a probable case is carried out a confirmatory examination and it is positive, it will be considered as a confirmed case. On the contrary, if the result is negative or indeterminate, it will continue to be considered a probable case. 3. Probable case by imaging: suspicious case with negative RT-PCR result for SARS-CoV-2 but with a chest CT scan with characteristic images of COVID-19 according to the radiological report. 4. Probable case due to symptoms: person with sudden and complete loss of smell (anosmia) or taste (ageusia) without an explanation.
Saudi Arabia	No Probable case definition
Turkey	No Probable case definition
Philippines	1. Suspect case whose testing for COVID-19 is inconclusive 2. Suspect who tested positive for COVID-19 but whose test was not conducted in a national or subnational reference laboratory or officially accredited laboratory for COVID-19 confirmatory testing 3. Suspect case who died without undergoing any confirmatory testing
Indonesia	1. Suspected cases with SARI 2. Died with a convincing clinical picture of COVID-19 AND no RT-PCR laboratory results
Israel	Israel does not have official surveillance case definitions; individuals are considered suspect based on contact with confirmed cases determined by digital surveillance of cellphones
Ukraine	A suspected case for whom lab testing cannot be unambiguously interpreted

†World Health Organization definition

‡ European Centres for Disease Control and Prevention Definition

533

534

535 Appendix 3. Confirmed Definitions

Country	Definition
WHO	
Iraq†	A person with laboratory confirmation of 2019-nCoV infection, irrespective of clinical signs and symptoms.
Bangladesh†	
Philippines†	1. Any individual, irrespective of presence or absence of clinical signs and symptoms, who was laboratory confirmed for COVID-19 in a test conducted at the national reference laboratory, a subnational reference laboratory, and/or DOH-licensed COVID-19 testing laboratory 2. Any suspect or probable COVID-19 cases, who tested positive using antigen tests in areas without breaks and/or in remote settings where RT-PCR is not immediately available; provided that the antigen tests satisfy the recommended minimum regulatory, technical and operational specifications set by the Health Technology Assessment
India	A person with laboratory confirmation of 2019-nCoV infection, irrespective of clinical signs and symptoms.
Pakistan	
USA	Meets confirmatory laboratory evidence (Detection of severe acute respiratory syndrome coronavirus 2 ribonucleic acid (SARS-CoV-2 RNA) in a clinical specimen using a molecular amplification detection test)
Italy‡	Any person meeting laboratory criteria (Detection of SARS-CoV-2 nucleic acid or antigen in a clinical specimen)
Germany‡	
France‡	
Brazil	1. Case of ILI or SARI with clinical confirmation associated with anosmia (olfactory dysfunction) OR ageusia (gustatory dysfunction) without any other previous cause. 2. Case of ILI or SARI with history of close or home contact, in the 14 days prior to appearance of signs and symptoms with confirmed case. 3. Case of ILI or SARI or death due to SARS that could not be confirmed by laboratory criteria AND that presents at least one (1) of the following tomographic changes: peripheral, bilateral, frosted glass opacity, with or without consolidation or visible intralobular lines ("paving"), Or Multifocal matte glass opacity with rounded morphology with or without consolidation or visible intralobular lines ("paving"), Or reverse halo sign or other findings of organizing pneumonia (seen later in the disease). 4. Case of ILI or SARI with test of positive result for SARS-CoV-2 performed by the RT-PCR method in real time. Or REAGENT result for IgM, IgA and / or IgG * performed by the following methods: Immunoenzymatic assay (Enzyme-Linked Immunosorbent Assay - ELISA); Immunochromatography (rapid test) for antibody detection; Electrochemiluminescence Immunoassay (ECLIA), Or Antigen Search: reagent result for SARS-CoV-2 by the Immunochromatography method for antigen detection . 5. Asymptomatic individuals with one of the following results: positive result for SARS-CoV-2 performed by the RT-PCR method in real time. Or immunological reagent result for IGM and / or IGA performed by the following methods: ELISA or Immunochromatography (rapid test) for antibody detection.
Russia	1. A positive laboratory test result for the presence of RNA SARS-CoV-2 using nucleic acid amplification techniques (NAAT) or SARS-CoV-2 antigen using immunochromatographic analysis regardless of clinical manifestations. 2. Positive result for IgA, IgM and / or IgG antibodies in patients with a clinically confirmed COVID-19 infection.
Colombia	Person with laboratory (RT-PCR for SARS-CoV-2 (IVIIS-C 59%, 13-69%) or Antigen detection test (alternative diagnosis. May change according to new evidence)) with positive results of active infection by the SARS-CoV-2 virus regardless of the presence or absence of clinical criteria, since the tests can be performed in asymptomatic, suspected or probable patients, with different prioritization.
Peru	1. Suspected case with a positive laboratory test for COVID 19, be it a reverse transcriptase polymerase chain reaction (RT-PCR) test in respiratory samples RT-PCR and / or a rapid IgM, IgG or IgG / IgM detection test. 2. Asymptomatic contact with a positive laboratory test for COVID-19.
Argentina	1. Confirmed by COVID-19 laboratory: any suspected cases with a detectable result for SARS-cov-2 by molecular biology tests by reverse transcriptase polymerase chain reaction (RT-PCR), by molecular biology tests by loop-mediated isothermal amplification reaction (LAMP), or SARS-cov-2 antigens by non-molecular tests. Confirmatory diagnosis in suspected cases with mild / moderate symptoms, only during the first 7 days from the onset of symptoms 2. Confirmed by clinical / epidemiological criteria COVID-19: In the last 14 days Has been in close contact with a confirmed case OR Is part of a conglomerate of cases, with at least one case confirmed by laboratory, with no other defined diagnosis, and presenting two or more of the following symptoms: fever, cough, odynophagia, difficulty breathing, vomiting / diarrhea / headache / myalgia 3. Any person who, in the absence of any other identified cause, begins with: Sudden loss of taste or smell 4. Any deceased person who: Do not have a defined etiological diagnosis Has had a clinical picture compatible with COVID-19 (known by the certifying doctor or referred by third parties) Regardless of previous health status and that it has been close contact of a confirmed case or has been epidemiologically linked to a cluster of cases or to areas of sustained community transmission.
Spain	1. Person who meets clinical criteria for a suspected case and with a positive diagnostic test. 2. Asymptomatic person with positive diagnostic test with negative IgG or not performed.
Mexico	1. Person who meets the operational definition of suspected case and has a diagnosis laboratory confirmed issued by InDRE. 2. Person who meets the operational definition of a suspected case, but who has been in contact with a laboratory confirmed case within the last 14 days from the date of onset of symptoms.
South Africa	A person with laboratory confirmation of SARS-CoV-2 infection (using an RT-PCR assay), irrespective of clinical signs and symptoms.

United Kingdom	Positive COVID-19 test result
Iran	Laboratory confirmation with or without suspect or probable criteria
Chile	1. Anyone who meets the definition of a suspected case in which the specific test for SARS-CoV-2 was positive (RT-PCR). 2. Any asymptomatic person identified through an active search strategy in which the specific test for SARS-CoV-2 was positive (RT-PCR).
Saudi Arabia	A person who meets the suspected case definition with laboratory confirmation of COVID-19 infection (PCR).
Turkey	Cases in which SARS-CoV-2 is detected by molecular methods among the cases matching the possible case definition.
Indonesia	A person who has tested positive for the COVID-19 virus proven by the RT-PCR laboratory examination. Confirmation cases are divided into: Confirmation case with symptoms (symptomatic), Confirmation cases without symptoms (asymptomatic)
Israel	Positive COVID-19 test result
Ukraine	A person with a laboratory confirmed COVID-19 disease, regardless of clinical signs and symptoms.

†World Health Organization definition

‡ European Centres for Disease Control and Prevention Definition

537 **Appendix 4. Country Testing Policies for Asymptomatic Individuals**

Countries	Asymptomatic testing	EPI Criteria: Confirmed Contact	EPI Criteria: Healthcare employee
WHO	Yes with EPI Criteria	Yes	
Iraq	Yes with EPI Criteria	Yes	
Bangladesh	No		
Philippines	Yes		
India	Yes with EPI Criteria	Yes	Yes
Pakistan	Yes		
USA	Yes		
Italy	Yes		
Germany	Yes with EPI Criteria	Yes	Yes
France	Yes		
Brazil	Yes with EPI Criteria	Yes	Yes
Russia	Yes		
Colombia	No		
Peru	No		
Argentina	No		
Spain	Yes with EPI Criteria	Yes	Yes
Mexico	No		
South Africa	Yes with EPI Criteria	Yes	
UK	No		Yes
Iran	Yes with EPI Criteria	Yes	
Chile	Yes		
Saudi Arabia	No		Yes
Turkey	Yes with EPI Criteria	Yes	Yes
Indonesia	No		
Israel	Yes		
Ukraine	No		

538